#pharma #HIV #GileadSciences #MSD #lenacapavir #islatravir #clinicaltrials #infectiousdiseases #Gilead #oralHIVtreatment #HIVtreatment #phase3trials #capsidinhibitor #ISLEND1trial #ISLEND2trial #antiretroviraltherapy #ART #FDA #Sunlenca #MDRHIV #HIVpreexposureprophylaxis #PrEP #NNRTI
zurl.co/gq0wN
zurl.co/gq0wN
Gilead, MSD share data on once-weekly oral HIV treatment
Gilead/MSD's once-weekly oral medicine for HIV has been shown to achieve high rates of viral suppression in phase 3, setting up regulatory filings.
pharmaphorum.com
August 20, 2026 at 7:59 AM